Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his life by 30 years.
We evaluated the effect of LynΔN overexpression on imatinib sensitivity of the chronic myelogenous leukemia (CML) cell line K562. Therefore, we generated stable cells that express plasmids ...
The study compared the MMR rate of Scemblix to investigator-selected standard-of-care tyrosine kinase inhibitors and to imatinib alone in adult patients with newly diagnosed Philadelphia ...
We examined the involvement of sphingosine kinase-1 (SphK1), which governs the ceramide/sphingosine-1-phosphate balance, in susceptibility to imatinib of either sensitive or resistant chronic ...